NO862123L - Fremgangsmaate for fremstilling av terapeutisk aktive spiroimidazolidiner. - Google Patents

Fremgangsmaate for fremstilling av terapeutisk aktive spiroimidazolidiner.

Info

Publication number
NO862123L
NO862123L NO862123A NO862123A NO862123L NO 862123 L NO862123 L NO 862123L NO 862123 A NO862123 A NO 862123A NO 862123 A NO862123 A NO 862123A NO 862123 L NO862123 L NO 862123L
Authority
NO
Norway
Prior art keywords
imidazolidine
formula
compound
mol
reaction
Prior art date
Application number
NO862123A
Other languages
English (en)
Norwegian (no)
Inventor
Christopher Andrew Lipinski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO862123L publication Critical patent/NO862123L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO862123A 1985-05-29 1986-05-28 Fremgangsmaate for fremstilling av terapeutisk aktive spiroimidazolidiner. NO862123L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/738,924 US4575507A (en) 1985-05-29 1985-05-29 Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use

Publications (1)

Publication Number Publication Date
NO862123L true NO862123L (no) 1986-12-01

Family

ID=24970055

Family Applications (1)

Application Number Title Priority Date Filing Date
NO862123A NO862123L (no) 1985-05-29 1986-05-28 Fremgangsmaate for fremstilling av terapeutisk aktive spiroimidazolidiner.

Country Status (21)

Country Link
US (1) US4575507A (de)
EP (1) EP0203791B1 (de)
JP (1) JPS61277671A (de)
KR (1) KR890001548B1 (de)
AT (1) ATE46332T1 (de)
AU (1) AU560429B2 (de)
DD (5) DD264214A5 (de)
DE (1) DE3665584D1 (de)
DK (1) DK248886A (de)
EG (1) EG17859A (de)
ES (2) ES8800228A1 (de)
FI (1) FI862251A7 (de)
GR (1) GR861388B (de)
HU (4) HU199845B (de)
IL (1) IL78954A (de)
NO (1) NO862123L (de)
NZ (1) NZ216334A (de)
PH (1) PH22213A (de)
PL (5) PL147397B1 (de)
PT (1) PT82650B (de)
ZA (1) ZA863934B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000807A1 (en) * 1984-07-20 1986-02-13 Pfizer Inc. Spiro-imidazolones for treatment of diabetes complications
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
AU598366B2 (en) * 1987-03-20 1990-06-21 Alcon Laboratories, Inc. Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes
US5202339A (en) * 1987-08-28 1993-04-13 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US5004751A (en) * 1987-08-28 1991-04-02 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
WO1990002126A1 (en) * 1988-08-24 1990-03-08 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US5068332A (en) * 1990-10-12 1991-11-26 American Home Products Corporation Alkylidene analogs of 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones useful as aldose reductase inhibitors
US8326636B2 (en) * 2008-01-16 2012-12-04 Canyon Ip Holdings Llc Using a physical phenomenon detector to control operation of a speech recognition engine
JP6105631B2 (ja) * 2012-02-09 2017-03-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，４−保護９−ヒドロキシ−５−オキソ−１，４−ジアザ−スピロ［５．５］ウンデカンの立体選択的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4117230A (en) 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
EP0109231B1 (de) * 1982-11-10 1986-10-22 Pfizer Inc. Sorbinil durch optische Aufspaltung mit Aminopinanderivaten
SU1380610A3 (ru) * 1982-12-06 1988-03-07 Пфайзер Инк. (Фирма) Способ получени спирогетероазолидиндионов или их фармацевтически приемлемых солей
US4556670A (en) 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
EP0159143B1 (de) * 1984-03-23 1987-12-16 Pfizer Inc. Spiro-Indene und Spiro-1,2-Dihydro-Naphthalene für die Behandlung von diabetischen Komplikationen
US4762838A (en) 1985-08-30 1988-08-09 Pfizer Inc. Quinazolin-4(3H)-one derivatives as anticoccidial agents

Also Published As

Publication number Publication date
HUT44767A (en) 1988-04-28
HU199845B (en) 1990-03-28
JPS61277671A (ja) 1986-12-08
EP0203791B1 (de) 1989-09-13
PL266365A1 (en) 1988-03-03
DD273258A5 (de) 1989-11-08
PT82650B (pt) 1988-11-30
AU5801286A (en) 1987-01-08
DD264213A5 (de) 1989-01-25
ES8800228A1 (es) 1987-11-01
EP0203791A1 (de) 1986-12-03
PL147398B1 (en) 1989-05-31
HUT49879A (en) 1989-11-28
DD264215A5 (de) 1989-01-25
ES557391A0 (es) 1988-02-16
KR890001548B1 (en) 1989-05-08
FI862251L (fi) 1986-11-30
NZ216334A (en) 1988-08-30
PL146020B1 (en) 1988-12-31
KR860008984A (ko) 1986-12-19
PL147399B1 (en) 1989-05-31
PL266363A1 (en) 1988-03-03
ATE46332T1 (de) 1989-09-15
DK248886A (da) 1986-11-30
IL78954A (en) 1989-09-28
IL78954A0 (en) 1986-09-30
HU196060B (en) 1988-09-28
PH22213A (en) 1988-06-28
HUT49882A (en) 1989-11-28
AU560429B2 (en) 1987-04-09
PL266364A1 (en) 1988-03-03
EG17859A (en) 1991-11-30
GR861388B (en) 1986-09-17
HU893127D0 (en) 1990-01-28
PL147397B1 (en) 1989-05-31
FI862251A7 (fi) 1986-11-30
DK248886D0 (da) 1986-05-28
ES8801830A1 (es) 1988-02-16
PT82650A (en) 1986-06-01
FI862251A0 (fi) 1986-05-28
US4575507A (en) 1986-03-11
PL147400B1 (en) 1989-05-31
PL266366A1 (en) 1988-03-03
ZA863934B (en) 1988-01-27
ES555375A0 (es) 1987-11-01
DE3665584D1 (de) 1989-10-19
DD264214A5 (de) 1989-01-25
DD251972A5 (de) 1987-12-02

Similar Documents

Publication Publication Date Title
EP0034063B1 (de) Hydantoinamine und deren pharmazeutische Zusammensetzungen
US4127665A (en) Thienohydantoin derivatives
NO862123L (no) Fremgangsmaate for fremstilling av terapeutisk aktive spiroimidazolidiner.
US5066659A (en) Spiro-heteroazalones for treatment of diabetic complications
IE48585B1 (en) Spiro-furanohydantoin derivatives,process for their preparation and pharmaceutical compositions containing them
CA1244443A (en) Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications
US4556670A (en) Spiro-3-hetero-azolones for treatment of diabetic complications
EP0127412B1 (de) Imidazolidinedion-Derivate
EP0180421B1 (de) Spiro-Hydantoine für die Behandlung von diabetischen Komplikationen
EP0136143B1 (de) Spirosuccinimide und ihre Anwendung in der Behandlung von Zuckerkrankheitskomplikationen
EP0173497B1 (de) Tetracyclische Spiro-Hydantoin-Aldose-Reduktase-Inhibitoren
US4766141A (en) Spiro-succinimides for treatment of diabetes complications
US4533667A (en) Imidazolidinedione derivatives
EP0171213B1 (de) Spiro-imidazolone für die Behandlung von diabetischen Komplikationen
IE49659B1 (en) Spiro-quinolone hydantoins,pharmaceutical compositions containing them,and processes for their preparation
CA1292992C (en) Spiro-heteroazolones for treatment of diabetes complications
DK157996B (da) Analogifremgangsmaade til fremstilling af 5-(2-alkoxyphenyl)-hydantoinderivater eller farmaceutisk acceptable salte deraf
CS244683B2 (en) Production method of spiro-3-hereroazolanes
KR860001870B1 (ko) 이미다졸리딘디온 유도체의 제조방법
EP0112620A1 (de) 5-(Substituierte Phenyl)-Hydantoine